Table 2.
Treatment characteristics of nonvaccinated and vaccinated patients
| Nonvaccinated (N = 38) N (%) |
Vaccinated (N = 26) N (%) |
P value | |
|---|---|---|---|
| Sex | |||
| Male | 21 (55.3) | 17 (65.4) | .418 |
| Female | 17 (44.7) | 9 (34.6) | |
| Age, median (IQR) | 55.5 (34.75-65.50) | 59 (47.0-66.75) | .124 |
| Diagnosis | |||
| Diffuse large B-cell lymphoma | 30 (78.9) | 19 (73.1) | .792 |
| High-grade B-cell lymphoma with MYC and BCL2/BCL6 | 1 (2.6) | 1 (3.8) | |
| Primary mediastinal B-cell lymphoma | 3 (7.9) | 1 (3.8) | |
| Transformed follicular lymphoma | 1 (2.6) | 1 (3.8) | |
| Mantle cell lymphoma | 0 (0) | 2 (7.6) | |
| Follicular lymphoma | 1 (2.6) | 2 (7.6) | |
| B-ALL | 2 (5.2) | 0 (0) | |
| Number of previous lines of therapy, median (IQR) | 3 (3-4) | 3.5 (3-5) | .083 |
| Previous auto HSCT | 9 (23.7) | 7 (25.0) | .769 |
| Time since auto HSCT, days median (IQR) | 603 (477-1266) | 1051 (846-2046) | |
| CAR T-cell product | .784 | ||
| Axicabtagene ciloleucel | 19 (50.0) | 13 (50.0) | |
| Lisocabtagene maraleucel | 1 (2.6) | 0 (0) | |
| Tisagenlecleucel | 17 (44.7) | 10 (38.5) | |
| Other | 0 (0) | 2 (7.7) | |
| Unknown | 1 (2.8) | 1 (3.8) | |
| CAR T-cell therapy conditioning | .404 | ||
| Fludarabine/cyclophosphamide | 35 (92.1) | 26 (100) | |
| Bendamustine | 1 (2.6) | 0 (0) | |
| Other | 1 (2.6) | 0 (0) | |
| Unknown | 1 (2.6) | 0 (0) | |
| Time since CAR T-cell infusion, days median (IQR) | 159 (37-305) | 386 (124-747) | <.001 |
| Variant of SARS-CoV-2 infection | <.001 | ||
| Wild-type | 7 (18.4) | 0 (0) | |
| Alpha mutation | 1 (2.6) | 2 (7.7) | |
| Delta mutation | 1 (2.6) | 3 (11.5) | |
| Omicron mutation | 4 (10.5) | 14 (53.8) | |
| Unknown | 25 (65.8) | 7 (25.0) | |
| Number of vaccinations | <.001 | ||
| 0 | 38 (100) | 0 (0) | |
| 1 | 0 (0) | 1 (3.8) | |
| 2 | 0 (0) | 18 (69.2) | |
| 3 | 0 (0) | 3 (11.5) | |
| 4 | 0 (0) | 4 (15.4) | |
| Timing of vaccination | <.001 | ||
| Before CAR T-cell infusion | 0 (0) | 10 (38.5) | |
| After CAR T-cell infusion | 0 (0) | 16 (61.5) | |
| Comorbidities∗ | .404 | ||
| Not present | 16 (42.1) | 14 (53.8) | |
| 1 comorbidity | 11 (28.9) | 10 (38.5) | |
| 2 comorbidities | 6 (15.8) | 1 (3.8) | |
| ≥3 comorbidities | 5 (13.1) | 1 (3.8) | |
| Leukocyte count (cells per mm3) at COVID-19 diagnosis, median (IQR) | 2465 (1282-3947) | 2550 (1900-3922) | .590 |
| Lymphocyte count (cells per mm3) at COVID-19 diagnosis, median (IQR) | 420 (215-1070) | 500 (300-697) | .985 |
| Neutrophil count (cells per mm3) at COVID-19 diagnosis, median (IQR) | 1300 (555-2450) | 1480 (690-2515) | .677 |
| Severity of infection | |||
| At home | 8 (21.2) | 7 (23.1) | .847 |
| Admitted to the hospital | 30 (78.9) | 19 (73.1) | |
| Duration of hospitalization, days median (IQR) | 27.5 (15-43.8) | 7 (6-16) | .022 |
| Admitted to the ICU | 14 (36.8) | 4 (15.4) | .054 |
| Duration of ICU admittance, days median (IQR) | 9 (4.50-29.25) | 23 (6.50-51.50) | .481 |
| Treatment with MoAbs | 3 (7.9) | 11 (42.3) | <.001 |
| Treatment with convalescent plasma | 11 (28.9) | 5 (19.2) | .378 |
| Treatment with viral replication inhibitor | 12 (31.6) | 6 (23.1) | .457 |
| Treatment with steroids | 17 (44.7) | 13 (50.0) | .679 |
| Treatment with tocilizumab | 2 (5.3) | 4 (15.4) | .172 |
| Outcome | |||
| Alive | 21 (68.4) | 20 (76.9) | |
| Dead | 15 (39.5) | 6 (23.1) | .209 |
| Cause of death | |||
| COVID-19 or contributed by COVID-19 | 12 (31.6) | 4 (15.4) | .142 |
| Hematological malignancy | 3 (7.9) | 2 (7.7) | .589 |
ALL, acute lymphoid leukemia; auto HSCT, autologous HSCT.
∗
One or more comorbidities present (chronic cardiomyopathy, chronic pulmonary disease, diabetes, liver disease, obesity, renal impairment, smoker).